RxDoctor Payments Data

Megan Walker, MD

Gastroenterology · Indianapolis, INNPI 1124384326

Payments from drug & device makers

$803in general payments, 2019–2025

Across 26 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$545
  • Pfizer$125
  • Lilly USA, LLC$48
  • AbbVie$28
  • Novo Nordisk$25
  • Nestle Healthcare Nutrition Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$68886%
  • Education$11514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$803 in reported general payments places this provider in the 25th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$20,954
Medicare patients
103
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa11$210,324
RinvoqUpadacitinib21$147,909
Humira(Cf) PenAdalimumab11$136,154
Mesalamine12$8,520
LinzessLinaclotide14$7,827
Colestipol Hcl21$1,730
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,313
Budesonide DrBudesonide16$1,222
Omeprazole37$696
LoperamideLoperamide Hcl15$645
Pantoprazole Sodium19$609
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl39$575
Dicyclomine Hcl15$391
Azathioprine12$242
Famotidine27$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$28$155,73635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →